Case Study #1

Problem

Pharmaceutical client could not obtain desired compound for preclinical work

Three different contractors tried to synthesize over a two-year period

Solution

Drug Discovery Alliances selected the appropriate partner to make desired compound for pre-IND needs and Phase-1 clinical trials

The CRO partner is the global leader in process chemistry with a staff comprised of entirely PhD process chemists with decades of pharmaceutical experie

Outcome

$300 million dollars was realized by client who licensed this asset to a pharmaceutical company

$1 billion dollars in potential down-stream revenues

Author
Recent Posts

Deborah Minor

CEO at Drug Discovery Alliances

Deborah has decades of business development experience marketing contract services, drug licensing and new technologies to the pharmaceutical industry. She founded Drug Discovery Alliances, Inc. in 2001 to connect pharmaceutical and biotech companies with top industry contractors who facilitate and speed projects. Deborah earned a Ph.D. in Medicinal Chemistry from University of North Carolina, Chapel Hill and has worked as an organic chemist for Rhone Poulenc. She subsequently worked for Accelyrs and MDL, marketing molecular modeling technologies and databases including Beilstein and Crossfire to the pharmaceutical industry.